import React from 'react';
import _ from 'lodash';
import { Linkout } from 'app/shared/links/Linkout';
import { PMIDLink } from 'app/shared/links/PMIDLink';
import { concatElements, concatElementsByComma } from 'app/shared/utils/Utils';
import { DefaultTooltip } from 'cbioportal-frontend-commons';
import * as styles from 'app/index.module.scss';

const FDA_ORIGIN_DATA =
  '[{"gene":"BRAF","alteration":"V600E","cancerType":"Melanoma","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":" Dabrafenib: https://wayback.archive-it.org/7993/20170112023855/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199.htm Vemurafenib: http://wayback.archive-it.org/7993/20170113081131/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm268301.htm Trametinib: https://wayback.archive-it.org/7993/20170112023855/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199.htm Binimetinib+Encorafenib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-and-binimetinib-combination-unresectable-or-metastatic-melanoma-braf Vemurafenib+Cobimetinib: https://wayback.archive-it.org/7993/20170111160758/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471934.htm Trametinib+Dabrafenib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-plus-trametinib-adjuvant-treatment-melanoma-braf-v600e-or-v600k-mutations ","drugLabel":"Dabrafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s010lbl.pdf Vemurafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf Trametinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204114s009lbl.pdf Binimetinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf Encorafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf Cobimetinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206192s002lbl.pdf ","drugLabelDate":"Dabrafenib: (5/2018) Vemurafenib: (11/2017) Trametinib: (5/2018) Binimetinib: (6/2018) Encorafenib: (6/2018) Cobimetinib: (1/2018)","pmids":"22735384, 23051966, 22608338 24508103, 28961848, 25399551 22663011, 25265492, 29361468  29573941  25265494, 27480103 23020132, 25287827, 25265492, 28991513, 28891408","abstracts":null},{"gene":"ERBB2","alteration":"Amplification","cancerType":"Breast Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Ado-Trastuzumab Emtansine: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ado-trastuzumab-emtansine-early-breast-cancer Neratinib: https://wayback.archive-it.org/7993/20190423192002/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567309.htm Lapatinib: http://wayback.archive-it.org/7993/20170113081156/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm203522.htm Trastuzumab: http: Trastuzumab+Pertuzumab: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pertuzumab-adjuvant-treatment-her2-positive-breast-cancer","drugLabel":"Ado-Trastuzumab Emtansine: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf Lapatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf Neratinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf Trastuzumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf Pertuzumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf","drugLabelDate":"Ado-Trastuzumab Emtansine: (5/2019) Lapatinib: (12/2018) Neratinib: (7/2017)  Trastuzumab: (11/2018) Pertuzumab: (12/2017)","pmids":"23020162, 30516102 17192538, 19786658 26874901, 29146401, 30274983, 30860945 16236738 22257673, 19060928, 16091755 23602601, 22149875, 22153890, 29320312, 31647503","abstracts":null},{"gene":"EGFR","alteration":"G719","cancerType":"Non-Small Cell Lung Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Afatinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr","drugLabel":"Afatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf","drugLabelDate":"Afatinib: (1/2018)","pmids":"22452895, 23816960, 25589191 ","abstracts":null},{"gene":"EGFR","alteration":"L861Q","cancerType":"Non-Small Cell Lung Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Afatinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr","drugLabel":"Afatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf","drugLabelDate":"Afatinib: (1/2018) ","pmids":"22452895, 23816960, 25589191","abstracts":null},{"gene":"EGFR","alteration":"S768I","cancerType":"Non-Small Cell Lung Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Afatinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr","drugLabel":"Afatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf","drugLabelDate":"Afatinib: (1/2018) ","pmids":"22452895, 23816960, 25589191 ","abstracts":null},{"gene":"ALK","alteration":"Oncogenic Mutations","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Brigatinib: https://www.fda.gov/drugs/resources-information-approved-drugs/brigatinib Lorlatinib: https://www.fda.gov/drugs/fda-approves-lorlatinib-second-or-third-line-treatment-alk-positive-metastatic-nsclc","drugLabel":"Brigatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf Lorlatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf","drugLabelDate":"Brigatinib: (4/2017) Lorlatinib: (11/2018)","pmids":"28475456, 30280657, 29768119 30413378, 27432227, 29074098 ","abstracts":null},{"gene":"KRAS","alteration":"Wildtype","cancerType":"Colorectal Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Cetuximab: http://wayback.archive-it.org/7993/20170113081107/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm310933.htm Regorafenib: http://wayback.archive-it.org/7993/20170113081059/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm321378.htm","drugLabel":"Cetuximab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf Panitumumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125147s207lbl.pdf Regorafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203085s007lbl.pdf","drugLabelDate":"Cetuximab: (4/2019) Panitumumab: (6/2017) Regorafenib: (4/2017)","pmids":"19339720, 15677699, 24739896 20921465, 20921462, 31268481 23177514 ","abstracts":null},{"gene":"ALK","alteration":"Fusions","cancerType":"Non-Small Cell Lung Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Crizotinib: http://wayback.archive-it.org/7993/20170113081129/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm270058.htm Ceritinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-ceritinib-indication-previously-untreated-alk-positive-metastatic-nsclc Alectinib: https://www.fda.gov/drugs/resources-information-approved-drugs/alectinib-approved-alk-positive-metastatic-non-small-cell-lung-cancer-nsclc","drugLabel":"Crizotinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202570s028lbl.pdf Ceritinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205755s009lbl.pdf Alectinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208434s003lbl.pdf","drugLabelDate":"Crizotinib: (6/2019) Ceritinib: (5/2017) Alectinib: (11/2017)","pmids":"23724913 28126333 28586279, 30215676, 29668860 ","abstracts":null},{"gene":"ROS1","alteration":"Fusions","cancerType":"Non-Small Cell Lung Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Crizotinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-capsules Entrectinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc","drugLabel":"Crizotinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202570s028lbl.pdf Entrectinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf","drugLabelDate":"Crizotinib: (6/2019) Entrectinib: (8/2019)","pmids":"25264305, 30980071, 29596029 28183697 ","abstracts":"Drilon et al. Abstract# CT060, AACR 2017: https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060\\r"},{"gene":"ABL1","alteration":"BCR-ABL1 Fusion","cancerType":"Chronic Myelogenous Leukemia","specimen":"Peripheral human whole blood or bone marrow","fdaLevel":"Level 2","fdaApproval":"Dasatinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dasatinib-pediatric-patients-cml Bosutinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-bosutinib-treatment-newly-diagnosed-ph-cml Nilotinib: http://wayback.archive-it.org/7993/20170113081235/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129238.htm","drugLabel":"Imatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf Dasatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf Bosutinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf Nilotinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022068s026lbl.pdf","drugLabelDate":"Imatinib: (7/2018) Dasatinib: (12/2018) Bosutinib: (9/2012) Nilotinib: (12/2017)","pmids":"11287972, 11287973, 12637609, 28095277 20525995, 27217448 29091516 20525993, 23502220, 28218239","abstracts":"Mauro, M. et al. Abstract# TPS7081, ASCO 2018: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS7081\\r"},{"gene":"IDH2","alteration":"Oncogenic Mutations","cancerType":"Acute Myeloid Leukemia","specimen":"Human blood (EDTA) or bone marrow (EDTA)","fdaLevel":"Level 2","fdaApproval":"Enasidenib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-granted-regular-approval-enasidenib-treatment-relapsed-or-refractory-aml","drugLabel":"Enasidenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf","drugLabelDate":"Enasidenib: (8/2017)","pmids":28588020,"abstracts":null},{"gene":"FGFR2","alteration":"Fusions","cancerType":"Bladder Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Erdafitinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma","drugLabel":"Erdafitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf","drugLabelDate":"Erdafitinib: (4/2019)","pmids":"26324363, 31340094 27870574, 30745300 ","abstracts":null},{"gene":"FGFR3","alteration":"Fusions","cancerType":"Bladder Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Erdafitinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma","drugLabel":"Erdafitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf","drugLabelDate":"Erdafitinib: (4/2019)","pmids":"26324363, 31340094 30745300, 29848605 ","abstracts":null},{"gene":"FGFR3","alteration":"G370C","cancerType":"Bladder Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Erdafitinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma","drugLabel":"Erdafitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf","drugLabelDate":"Erdafitinib: (4/2019)","pmids":"26324363, 31340094  27870574, 29848605, 30745300, 21119661 ","abstracts":null},{"gene":"FGFR3","alteration":"R248C","cancerType":"Bladder Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Erdafitinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma","drugLabel":"Erdafitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf","drugLabelDate":"Erdafitinib: (4/2019)","pmids":"26324363, 31340094 27870574, 29848605, 30745300, 21119661 ","abstracts":null},{"gene":"FGFR3","alteration":"S249C","cancerType":"Bladder Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Erdafitinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma","drugLabel":"Erdafitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf","drugLabelDate":"Erdafitinib: (4/2019)","pmids":"26324363, 31340094  27870574, 29848605, 30745300, 21119661 ","abstracts":null},{"gene":"FGFR3","alteration":"Y373C","cancerType":"Bladder Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Erdafitinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma","drugLabel":"Erdafitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf","drugLabelDate":"Erdafitinib: (4/2019)","pmids":"26324363, 31340094  27870574, 29848605, 30745300, 21119661 ","abstracts":null},{"gene":"EGFR","alteration":"729_761del","cancerType":"Non-Small Cell Lung Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Erlotinib: https://www.fda.gov/drugs/resources-information-approved-drugs/erlotinib-tarceva Afatinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr Gefitinib: https://wayback.archive-it.org/7993/20170112222747/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm454678.htm Dacomitinib: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0 Osimertinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-first-line-treatment-metastatic-nsclc-most-common-egfr-mutations","drugLabel":"Erlotinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf Afatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf Gefitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdf Dacomitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Osimertinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf","drugLabelDate":"Erlotinib: (10/2016) Afatinib: (1/2018) Gefitinib: (8/2018) Dacomitinib: (9/2018)  Osimertinib: (4/2018)","pmids":"22285168, 27987585 22452895, 23816960, 25589191 19692680, 21670455, 20573926, 20022809, 22370314, 28958502, 29864379, 22285168, 27987585 29151359, 30659024 ","abstracts":null},{"gene":"EGFR","alteration":"L858R","cancerType":"Non-Small Cell Lung Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Erlotinib: https://www.fda.gov/drugs/resources-information-approved-drugs/erlotinib-tarceva Afatinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr Gefitinib: https://wayback.archive-it.org/7993/20170112222747/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm454678.htm Dacomitinib: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0 Osimertinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-first-line-treatment-metastatic-nsclc-most-common-egfr-mutations","drugLabel":"Erlotinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf Afatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf Gefitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdf Dacomitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Osimertinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf","drugLabelDate":"Erlotinib: (10/2016) Afatinib: (1/2018) Gefitinib: (8/2018) Dacomitinib: (9/2018)  Osimertinib: (4/2018)","pmids":"22285168, 27987585 22452895, 23816960, 25589191 19692680, 21670455, 20573926, 20022809, 22370314, 28958502, 29864379, 22285168, 27987585 29151359, 30659024","abstracts":"Ramalingam et al. Abstract# LBA5_PR, ESMO 2019: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2019-Congress/Osimertinib-vs-comparator-EGFR-TKI-as-first-line-treatment-for-EGFRm-advanced-NSCLC-FLAURA-Final-overall-survival-analysis\\r"},{"gene":"TSC1","alteration":"Oncogenic Mutations","cancerType":"CNS Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Everolimus: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-everolimus-tuberous-sclerosis-complex-associated-partial-onset-seizures","drugLabel":"Everolimus: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022334s040,203985s013lbl.pdf","drugLabelDate":"Everolimus: (4/2018)","pmids":23158522,"abstracts":null},{"gene":"TSC2","alteration":"Oncogenic Mutations","cancerType":"CNS Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Everolimus: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-everolimus-tuberous-sclerosis-complex-associated-partial-onset-seizures","drugLabel":"Everolimus: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022334s040,203985s013lbl.pdf","drugLabelDate":"Everolimus: (4/2018)","pmids":23158522,"abstracts":null},{"gene":"PIK3CA","alteration":"Oncogenic Mutations","cancerType":"Breast Cancer","specimen":"FFPE or or circulating tumor DNA (ctDNA) from plasma derived from K2EDTA anticoagulated peripheral whole blood ","fdaLevel":"Level 2","fdaApproval":"Fulvestrant+Alpelisib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer ","drugLabel":" Alpelisib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf","drugLabelDate":"Alpelisib: (5/2019)","pmids":"31091374, 25877889, 30543347 ","abstracts":"Edgar et al. Abstract# 156, AACR 2017: https://cancerres.aacrjournals.org/content/77/13_Supplement/156\\r"},{"gene":"FLT3","alteration":"572_630ins (ITD)","cancerType":"Acute Myeloid Leukemia","specimen":"Mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia (AML)","fdaLevel":"Level 2","fdaApproval":"Gilteritinib: https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation","drugLabel":"Gilteritinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf","drugLabelDate":"Gilteritinib: (11/2018)","pmids":"28516360, 28645776 24227820 29859851, 29875101, 31175001 18230792, 22368270 ","abstracts":"Cortes, J. et al. Abstract# LB2600, EHA 2017: https://library.ehaweb.org/eha/2018/stockholm/218882/jorge.cortes.quizartinib.significantly.prolongs.overall.survival.in.patients.html\\r"},{"gene":"FLT3","alteration":"I836","cancerType":"Acute Myeloid Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Gilteritinib: https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation","drugLabel":"Gilteritinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf","drugLabelDate":"Gilteritinib: (11/2018)","pmids":"28516360, 28645776 ","abstracts":null},{"gene":"FLT3","alteration":"D835","cancerType":"Acute Myeloid Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Gilteritinib: https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation","drugLabel":"Gilteritinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf","drugLabelDate":"Gilteritinib: (11/2018)","pmids":"28516360, 28645776 ","abstracts":null},{"gene":"KIT","alteration":"Oncogenic Mutations","cancerType":"Gastrointestinal Stromal Tumor","specimen":"FFPE (C-KIT protein)","fdaLevel":"Level 2","fdaApproval":"Imatinib: http://wayback.archive-it.org/7993/20170113081112/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm289789.htm Regorafenib: https://wayback.archive-it.org/7993/20170112223048/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340958.htm","drugLabel":"Imatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf Sunitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021938s033lbl.pdf Regorafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203085s007lbl.pdf","drugLabelDate":"Imatinib: (07/2018)  Sunitinib: (11/2017) Regorafenib: (4/2017)","pmids":"12181401, 18235122, 18955451, 28196207 17046465  23177515 ","abstracts":null},{"gene":"PDGFB","alteration":"COL1A1-PDGFB Fusion","cancerType":"Dermatofibrosarcoma Protuberans","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Imatinib: http://wayback.archive-it.org/7993/20170113081305/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094941.htm","drugLabel":"Imatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf","drugLabelDate":"Imatinib: (7/2018)","pmids":"21128251, 15503291, 15746584, 19620561, 20439456, 15681532, 18451237 ","abstracts":null},{"gene":"PDGFRA","alteration":"FIP1L1-PDGFRA Fusion","cancerType":"Chronic Eosinophilic Leukemia, NOS","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Imatinib: http://wayback.archive-it.org/7993/20170113081305/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094941.htm","drugLabel":"Imatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf","drugLabelDate":"Imatinib: (7/2018)","pmids":18950453,"abstracts":null},{"gene":"PDGFRA","alteration":"Fusions","cancerType":"Myelodysplastic/Myeloproliferative Neoplasms","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Imatinib: http://wayback.archive-it.org/7993/20170113081305/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094941.htm","drugLabel":"Imatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf","drugLabelDate":"Imatinib: (7/2018)","pmids":"12660384, 14504092, 18950453, 17555450, 16498388, 16845659, 12944919, 15034867 ","abstracts":null},{"gene":"PDGFRB","alteration":"Fusions","cancerType":"Myelodysplastic/Myeloproliferative Neoplasms","specimen":"fresh bone marrow samples","fdaLevel":"Level 2","fdaApproval":"Imatinib: http://wayback.archive-it.org/7993/20170113081305/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094941.htm","drugLabel":"Imatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf","drugLabelDate":"Imatinib: (7/2018)","pmids":"12181402, 16960151, 18950453, 14504092, 26355392, 24687085, 12676775 ","abstracts":null},{"gene":"ABL1","alteration":"BCR-ABL1 Fusion","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Imatinib: https://wayback.archive-it.org/7993/20170112223107/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336868.htm Dasatinib: http://wayback.archive-it.org/7993/20170113081331/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095630.htm Ponatinib: http://wayback.archive-it.org/7993/20170113081052/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm332368.htm","drugLabel":"Imatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf Dasatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf Ponatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s022lbl.pdf","drugLabelDate":"Imatinib: (7/2018) Dasatinib: (12/2018) Ponatinib: (11/2016)","pmids":"12200353, 11287973, 24441288 17496201, 20131302, 21931113 24180494 19075254, 26040495,  24345751, 21865346, 22371878, 25132497 26065651, 16775235 ","abstracts":null},{"gene":"IDH1","alteration":"Oncogenic Mutations","cancerType":"Acute Myeloid Leukemia","specimen":"Human blood (EDTA) or bone marrow (EDTA)","fdaLevel":"Level 2","fdaApproval":"Ivosidenib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-first-line-treatment-aml-idh1-mutation","drugLabel":"Ivosidenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf","drugLabelDate":"Ivosidenib: (7/2018)","pmids":"23558169, 23393090, 29860938 ","abstracts":null},{"gene":"NTRK1","alteration":"Fusions","cancerType":"All Solid Tumors","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Larotrectinib: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0 Entrectinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc","drugLabel":"Larotrectinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf Entrectinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf","drugLabelDate":"Larotrectinib: (11/2018) Entrectinib: (8/2019)","pmids":"28183697 29466156, 26216294 ","abstracts":"Demetri et al. Abstract# LBA17, ESMO 2018 Congress: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Efficacy-and-Safety-of-Entrectinib-in-Patients-with-NTRK-Fusion-Positive-NTRK-fp-Tumors-Pooled-Analysis-of-STARTRK-2-STARTRK-1-and-ALKA-372-001&Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018: https://meetinglibrary.asco.org/record/155954/abstract\\r"},{"gene":"NTRK2","alteration":"Fusions","cancerType":"All Solid Tumors","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Larotrectinib: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0 Entrectinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc","drugLabel":"Larotrectinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf Entrectinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf","drugLabelDate":"Larotrectinib: (11/2018) Entrectinib: (8/2019)","pmids":"28183697 29466156, 26216294","abstracts":"Demetri et al. Abstract# LBA17, ESMO 2018 Congress: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Efficacy-and-Safety-of-Entrectinib-in-Patients-with-NTRK-Fusion-Positive-NTRK-fp-Tumors-Pooled-Analysis-of-STARTRK-2-STARTRK-1-and-ALKA-372-001&Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018: https://meetinglibrary.asco.org/record/155954/abstract\\r"},{"gene":"NTRK3","alteration":"Fusions","cancerType":"All Solid Tumors","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Larotrectinib: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0 Entrectinib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc","drugLabel":"Larotrectinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf Entrectinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf","drugLabelDate":"Larotrectinib: (11/2018) Entrectinib: (8/2019)","pmids":"28183697 29466156, 26216294","abstracts":"Demetri et al. Abstract# LBA17, ESMO 2018 Congress: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Efficacy-and-Safety-of-Entrectinib-in-Patients-with-NTRK-Fusion-Positive-NTRK-fp-Tumors-Pooled-Analysis-of-STARTRK-2-STARTRK-1-and-ALKA-372-001&Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018: https://meetinglibrary.asco.org/record/155954/abstract\\r"},{"gene":"FLT3","alteration":"Oncogenic Mutations","cancerType":"Acute Myeloid Leukemia","specimen":"Mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia (AML)","fdaLevel":"Level 2","fdaApproval":"Midostaurin: https://www.fda.gov/drugs/resources-information-approved-drugs/midostaurin","drugLabel":"Midostaurin: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf","drugLabelDate":"Midostaurin: (4/2017)","pmids":28644114,"abstracts":null},{"gene":"BRCA1","alteration":"Oncogenic Mutations","cancerType":"Ovarian Cancer","specimen":"FFPE Whole blood specimens collected in EDTA","fdaLevel":"Level 2","fdaApproval":"Niraparib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer Rucaparib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-rucaparib-maintenance-treatment-recurrent-ovarian-fallopian-tube-or-primary-peritoneal","drugLabel":"Niraparib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf Rucaparib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf","drugLabelDate":"Niraparib: (4/2020) Rucaparib: (4/2018)","pmids":"27717299, 30948273, 31562799, 25366685, 24882434, 30285518, 30345884  28882436, 28916367 NCCN Guidelines: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, Version 2.2019-September 17, 2019","abstracts":"Penson et al. Abstract# 5506, ASCO 2019: https://meetinglibrary.asco.org/record/173435/abstract\\r"},{"gene":"BRCA1","alteration":"Oncogenic Mutations","cancerType":"Peritoneal Serous Carcinoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Niraparib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer Rucaparib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-rucaparib-maintenance-treatment-recurrent-ovarian-fallopian-tube-or-primary-peritoneal","drugLabel":"Niraparib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf Rucaparib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf","drugLabelDate":"Niraparib: (4/2020) Rucaparib: (4/2018)","pmids":"27717299, 30948273, 31562799, 25366685, 24882434, 30285518, 30345884 28882436, 28916367 NCCN Guidelines: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, Version 2.2019-September 17, 2019","abstracts":"Penson et al. Abstract# 5506, ASCO 2019: https://meetinglibrary.asco.org/record/173435/abstract\\r"},{"gene":"BRCA2","alteration":"Oncogenic Mutations","cancerType":"Ovarian Cancer","specimen":"FFPE Whole blood specimens collected in EDTA","fdaLevel":"Level 2","fdaApproval":"Niraparib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer Rucaparib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-rucaparib-maintenance-treatment-recurrent-ovarian-fallopian-tube-or-primary-peritoneal","drugLabel":"Niraparib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf Rucaparib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf","drugLabelDate":"Niraparib: (4/2020) Rucaparib: (4/2018)","pmids":"27717299, 30948273, 31562799, 25366685, 24882434, 30285518, 30345884 28882436, 28916367 NCCN Guidelines: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, Version 2.2019-September 17, 2019","abstracts":"Penson et al. Abstract# 5506, ASCO 2019: https://meetinglibrary.asco.org/record/173435/abstract\\r"},{"gene":"BRCA2","alteration":"Oncogenic Mutations","cancerType":"Peritoneal Serous Carcinoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Niraparib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer Rucaparib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-rucaparib-maintenance-treatment-recurrent-ovarian-fallopian-tube-or-primary-peritoneal","drugLabel":"Niraparib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf Rucaparib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf","drugLabelDate":"Niraparib: (4/2020) Rucaparib: (4/2018)","pmids":"27717299, 30948273, 31562799, 25366685, 24882434, 30285518, 30345884 28882436, 28916367 NCCN Guidelines: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, Version 2.2019-September 17, 2019","abstracts":"Penson et al. Abstract# 5506, ASCO 2019: https://meetinglibrary.asco.org/record/173435/abstract\\r"},{"gene":"Other Biomarkers","alteration":"MSI-H","cancerType":"Colorectal Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Nivolumab: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-nivolumab-accelerated-approval-msi-h-or-dmmr-colorectal-cancer Nivolumab+Ipilimumab: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ipilimumab-msi-h-or-dmmr-metastatic-colorectal-cancer","drugLabel":"Nivolumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s034lbl.pdf Ipilimumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125377s096lbl.pdf","drugLabelDate":"Nivolumab: (7/2017) Ipilimumab: (7/2018)","pmids":"28734759 29355075 ","abstracts":"Andre et al. Abstract# 553, GCS 2018: https://meetinglibrary.asco.org/record/155742/abstract\\r"},{"gene":"EGFR","alteration":"T790M","cancerType":"Non-Small Cell Lung Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Osimertinib: https://www.fda.gov/drugs/resources-information-approved-drugs/osimertinib-tagrisso","drugLabel":"Osimertinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf","drugLabelDate":"Osimertinib: (4/2018)","pmids":"25923549, 27751847, 29151359, 30059262 23816963, 24478319, 26051236 ","abstracts":null},{"gene":"Other Biomarkers","alteration":"MSI-H","cancerType":"All Solid Tumors * (CDx = NSCLC, Gastric or Gastroesophageal Junction Carcinoma, Cervical Carncer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma)","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Pembrolizumab: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication","drugLabel":"Pembrolizumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s014lbl.pdf","drugLabelDate":"Pembrolizumab: (5/2017)","pmids":"28596308, 26028255, 30589920 ","abstracts":null},{"gene":"ABL1","alteration":"T315I","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Ponatinib: http://wayback.archive-it.org/7993/20170113081052/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm332368.htm","drugLabel":"Ponatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s022lbl.pdf","drugLabelDate":"Ponatinib: (11/2016)","pmids":"23190221, 29567798 , 24180494 17339191 , 18403620, 17768119, 21562040, 19075254  ","abstracts":null},{"gene":"ABL1","alteration":"T315I","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Ponatinib: http://wayback.archive-it.org/7993/20170113081052/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm332368.htm","drugLabel":"Ponatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s022lbl.pdf","drugLabelDate":"Ponatinib: (11/2016)","pmids":"24180494, 19878872, 23190221 18403620, 17768119, 17339191, 21562040, 19075254  ","abstracts":null},{"gene":"BRAF","alteration":"V600K","cancerType":"Melanoma","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Trametinib: https://wayback.archive-it.org/7993/20170112023855/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199.htm Binimetinib+Encorafenib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-and-binimetinib-combination-unresectable-or-metastatic-melanoma-braf Vemurafenib+Cobimetinib: https://wayback.archive-it.org/7993/20170111160758/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471934.htm Trametinib+Dabrafenib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-plus-trametinib-adjuvant-treatment-melanoma-braf-v600e-or-v600k-mutations","drugLabel":"Trametinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204114s009lbl.pdf Binimetinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf Encorafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf Vemurafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf Cobimetinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206192s002lbl.pdf Dabrafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s010lbl.pdf","drugLabelDate":"Trametinib: (5/2018) Binimetinib: (6/2018) Encorafenib: (6/2018) Vemurafenib: (11/2017) Cobimetinib: (1/2018) Dabrafenib: (5/2018)","pmids":"22663011, 25399551, 25265492, 29361468 29573941 25265494, 27480103 23020132, 25287827, 28991513, 28891408","abstracts":null},{"gene":"BRAF","alteration":"V600E","cancerType":"Anaplastic Thyroid Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Trametinib+Dabrafenib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-plus-trametinib-anaplastic-thyroid-cancer-braf-v600e-mutation","drugLabel":"Trametinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204114s009lbl.pdf Dabrafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s010lbl.pdf","drugLabelDate":"Trametinib: (5/2018) Dabrafenib: (5/2018)","pmids":29072975,"abstracts":null},{"gene":"BRAF","alteration":"V600E","cancerType":"Non-Small Cell Lung Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Trametinib+Dabrafenib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-dabrafenib-and-trametinib-combination-metastatic-nsclc-braf-v600e","drugLabel":"Trametinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204114s007lbl.pdf Dabrafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s010lbl.pdf","drugLabelDate":"Trametinib: (4/2018) Dabrafenib: (5/2018)","pmids":"27283860, 28919011","abstracts":null},{"gene":"ERBB2","alteration":"Amplification","cancerType":"Esophagogastric Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":"Trastuzumab: http://wayback.archive-it.org/7993/20170113081145/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm230418.htm","drugLabel":"Trastuzumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf","drugLabelDate":"Trastuzumab: (11/2018)","pmids":20728210,"abstracts":null},{"gene":"BRAF","alteration":"V600","cancerType":"Erdheim-Chester Disease","specimen":"NA","fdaLevel":"Level 3","fdaApproval":"Vemurafenib: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-granted-approval-vemurafenib-erdheim-chester-disease","drugLabel":"Vemurafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf","drugLabelDate":"Vemurafenib: (11/2017)","pmids":"29188284, 26287849","abstracts":null},{"gene":"ABL1","alteration":"E255K","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 17496201, 26040495  NCCN Guidelines, Acute Lymphoblastic Leukemia , Version 2.2019, May 15, 2019","abstracts":null},{"gene":"ABL1","alteration":"E255V","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 17496201, 26040495  NCCN Guidelines, Acute Lymphoblastic Leukemia, Version 2.2019, May 15, 2019","abstracts":null},{"gene":"ABL1","alteration":"F317C","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 26040495 NCCN Guidelines, Acute Lymphoblastic Leukemia , Version 2.2019, May 15, 2019","abstracts":null},{"gene":"ABL1","alteration":"F317I","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 26040495 NCCN Guidelines, Acute Lymphoblastic Leukemia, Version 2.2019, May 15, 2019","abstracts":null},{"gene":"ABL1","alteration":"F317L","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 26040495 NCCN Guidelines, Acute Lymphoblastic Leukemia, Version 2.2019, May 15, 2019","abstracts":null},{"gene":"ABL1","alteration":"F317V","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 26040495 NCCN Guidelines, Acute Lymphoblastic Leukemia, Version 2.2019, May 15, 2019","abstracts":null},{"gene":"ABL1","alteration":"F359C","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 17496201, 26040495  NCCN Guidelines, Acute Lymphoblastic Leukemia, Version 2.2019, May 15, 2019","abstracts":null},{"gene":"ABL1","alteration":"F359I","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 17496201, 26040495  NCCN Guidelines, Acute Lymphoblastic Leukemia , Version 2.2019, May 15, 2019","abstracts":null},{"gene":"ABL1","alteration":"F359V","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 17496201, 26040495  NCCN Guidelines, Acute Lymphoblastic Leukemia , Version 2.2019, May 15, 2019","abstracts":null},{"gene":"ABL1","alteration":"T315A","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 26040495 NCCN Guidelines, Acute Lymphoblastic Leukemia , Version 2.2019, May 15, 2019","abstracts":null},{"gene":"ABL1","alteration":"V299L","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 23086624, 15930265 NCCN Guidelines, Acute Lymphoblastic Leukemia , Version 2.2019, May 15, 2019","abstracts":null},{"gene":"ABL1","alteration":"Y253H","cancerType":"B-Lymphoblastic Leukemia/Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 17496201, 26040495  NCCN Guidelines, Acute Lymphoblastic Leukemia , Version 2.2019, May 15, 2019","abstracts":null},{"gene":"ABL1","alteration":"E255K","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 15930265, 19779040 NCCN Guidelines, Chronic Myeloid Leukemia, Version 1.2020 - August 26, 2019","abstracts":null},{"gene":"ABL1","alteration":"E255V","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 15930265, 19779040 NCCN Guidelines, Chronic Myeloid Leukemia, Version 1.2020 - August 26, 2019","abstracts":null},{"gene":"ABL1","alteration":"F317C","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 28599428, 15930265 NCCN Guidelines, Chronic Myeloid Leukemia, Version 1.2020 - August 26, 2019","abstracts":null},{"gene":"ABL1","alteration":"F317I","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 15930265, 19779040 NCCN Guidelines, Chronic Myeloid Leukemia, Version 1.2020 - August 26, 2019","abstracts":null},{"gene":"ABL1","alteration":"F317L","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 15930265, 19779040 NCCN Guidelines, Chronic Myeloid Leukemia, Version 1.2020 - August 26, 2019","abstracts":null},{"gene":"ABL1","alteration":"F317V","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 15930265, 19779040 NCCN Guidelines, Chronic Myeloid Leukemia, Version 1.2020 - August 26, 2019","abstracts":null},{"gene":"ABL1","alteration":"F359C","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 15930265, 19779040 NCCN Guidelines, Chronic Myeloid Leukemia, Version 1.2020 - August 26, 2019","abstracts":null},{"gene":"ABL1","alteration":"F359I","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 15930265, 19779040 NCCN Guidelines, Chronic Myeloid Leukemia, Version 1.2020 - August 26, 2019","abstracts":null},{"gene":"ABL1","alteration":"F359V","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 15930265, 19779040 NCCN Guidelines, Chronic Myeloid Leukemia, Version 1.2020 - August 26, 2019","abstracts":null},{"gene":"ABL1","alteration":"T315A","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 15930265, 19779040 NCCN Guidelines, Chronic Myeloid Leukemia, Version 1.2020 - August 26, 2019","abstracts":null},{"gene":"ABL1","alteration":"V299L","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 15930265, 23086624 NCCN Guidelines, Chronic Myeloid Leukemia, Version 1.2020 - August 26, 2019","abstracts":null},{"gene":"ABL1","alteration":"Y253H","cancerType":"Chronic Myelogenous Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"19075254, 15930265, 19779040 NCCN Guidelines, Chronic Myeloid Leukemia, Version 1.2020 - August 26, 2019","abstracts":null},{"gene":"AKT1","alteration":"E17K","cancerType":"Breast Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"23394218, 28489509, 26351323, 22294718","abstracts":null},{"gene":"AKT1","alteration":"E17K","cancerType":"Endometrial Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"23394218, 28489509, 26351323, 22294718","abstracts":null},{"gene":"AKT1","alteration":"E17K","cancerType":"Ovarian Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"23394218, 28489509, 26351323, 22294718","abstracts":null},{"gene":"ALK","alteration":"Fusions","cancerType":"Inflammatory Myofibroblastic Tumor","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"20979472, 23598171 24670165, 26020125 NCCN Guidelines, Soft Tissue Sarcoma, Version 4.2019 - September 12, 2019","abstracts":null},{"gene":"ARAF","alteration":"Oncogenic Mutations","cancerType":"Histiocytosis","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"30867592 26566875, 24569458","abstracts":null},{"gene":"ARAF","alteration":"Oncogenic Mutations","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":24569458,"abstracts":null},{"gene":"BRAF","alteration":"V600E","cancerType":"Colorectal Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"31566309, 29431699 NCCN Guidelines: Colon Cancer, Version 2.2019-May 15, 2019","abstracts":null},{"gene":"BRAF","alteration":"V600E","cancerType":"Hairy Cell Leukemia","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":26352686,"abstracts":null},{"gene":"BRAF","alteration":"Oncogenic Mutations","cancerType":"Histiocytosis","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"30867592, 29236635, 30718231","abstracts":null},{"gene":"BRAF","alteration":"Fusions","cancerType":"Melanoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"26314551, 26072686, 23890088, 24345920","abstracts":null},{"gene":"BRAF","alteration":"K601","cancerType":"Melanoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"28344857, 23248257, 24933606, 22798288, 29903896","abstracts":null},{"gene":"BRAF","alteration":"L597","cancerType":"Melanoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"28344857, 23248257, 24933606, 22798288, 29903896","abstracts":null},{"gene":"BRAF","alteration":"Fusions","cancerType":"Ovarian Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"26324360, 23890088, 24345920","abstracts":null},{"gene":"BRCA1","alteration":"Oncogenic Mutations","cancerType":"Breast Cancer","specimen":"Whole blood specimens collected in EDTA","fdaLevel":"Level 2","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"28578601, 30110579, 30563931 NCCN Guidelines: Breast Cancer, Version 3.2019-September 6, 2019","abstracts":"Pascual et al. JCOPO, 2019: https://ascopubs.org/doi/full/10.1200/PO.19.00012\\r"},{"gene":"BRCA2","alteration":"Oncogenic Mutations","cancerType":"Breast Cancer","specimen":"Whole blood specimens collected in EDTA","fdaLevel":"Level 2","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"28578601 30110579, 30563931 NCCN Guidelines: Breast Cancer, Version 3.2019-September 6, 2019","abstracts":null},{"gene":"CDK4","alteration":"Amplification","cancerType":"Dedifferentiated Liposarcoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"23569312, 27124835 NCCN Guidelines: Soft Tissue Sarcoma, Version 4.2019-September 12, 2019","abstracts":null},{"gene":"CDK4","alteration":"Amplification","cancerType":"Well-Differentiated Liposarcoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"23569312, 27124835 NCCN Guidelines: Soft Tissue Sarcoma, Version 4.2019-September 12, 2019","abstracts":null},{"gene":"EGFR","alteration":"A763_Y764insFQEA","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"23371856, 24353160, 23969006, 23328547, 24285021, 26515464 NCCN Guidelines: Non-Small Cell Lung Cancer, Version 7.2019-August 30, 2019","abstracts":null},{"gene":"EGFR","alteration":"729_761ins","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"22190593, 28336552, 29340050, 24389445, 25279299, 21841502, 31562956 23387505, 20075572, 28089594","abstracts":null},{"gene":"EGFR","alteration":"E709_T710delinsD","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"26206867, 31686847, 31187861, 28625646","abstracts":null},{"gene":"EGFR","alteration":"Kinase Domain Duplication","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"28336552 26286086","abstracts":"Wiest G, Kohlhauf el MMJ, Lakis S., et al. New Oncol Abstract #291 2016: http://www.newoncology.com/fileadmin/content/Download_pdfs/Wiest_et_al_DGHO-2016-Abstract_final.pdf\\r"},{"gene":"EGFR","alteration":"762_823ins","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"27188206, 29686424 18676761, 15897572, 17686547, 24353160, 19536777, 23371856, 21764376, 23328547, 24065731, 24893891","abstracts":null},{"gene":"ERBB2","alteration":"Oncogenic Mutations","cancerType":"Breast Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"29420467, 23220880","abstracts":null},{"gene":"ERBB2","alteration":"Oncogenic Mutations","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"29989854 29420467, 23220880 NCCN Guidelines: Non-Small Cell Lung Cancer, Version 7.2019-August 30, 2019","abstracts":null},{"gene":"ERBB2","alteration":"Amplification","cancerType":"Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"29584549 NCCN Guidelines: Uterine Neoplasms, Version 4.2019, September 16, 2019","abstracts":null},{"gene":"ERCC2","alteration":"Oncogenic Mutations","cancerType":"Bladder Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"27310333, 25096233, 12208738, 29980530","abstracts":null},{"gene":"ESR1","alteration":"Oncogenic Mutations","cancerType":"Breast Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"27269946, 27986707","abstracts":null},{"gene":"EZH2","alteration":"Oncogenic Mutations","cancerType":"Follicular Lymphoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":null,"abstracts":"Morschhauser et al. Abstract# S100, EHA 2018: https://library.ehaweb.org/eha/2018/stockholm/214434/gilles.salles.interim.update.from.a.phase.2.multicenter.study.of.tazemetostat.html\\r"},{"gene":"FGFR1","alteration":"Amplification","cancerType":"Lung Squamous Cell Carcinoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"27870574, 30745300, 23082000","abstracts":null},{"gene":"FGFR2","alteration":"Fusions","cancerType":"Cholangiocarcinoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"29182496, 30745300, 24122810, 31088831","abstracts":"Cleary et al. Abstract# 447, Gastrointestinal Cancer Symposium, 2018: https://meetinglibrary.asco.org/record/155948/abstract\\r"},{"gene":"FGFR3","alteration":"S371C","cancerType":"Bladder Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"27870574, 29848605, 26324363, 30745300, 21119661, 31088831","abstracts":"Siefker-Radtke et al. Abstract#4503, ASCO 2018: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4503\\r"},{"gene":"FGFR3","alteration":"K650","cancerType":"Bladder Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"27870574, 29848605, 26324363, 30745300, 21119661, 31088831","abstracts":"Siefker-Radtke et al. Abstract#4503, ASCO 2018: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4503\\r"},{"gene":"FGFR3","alteration":"G380R","cancerType":"Bladder Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"27870574, 29848605, 26324363, 30745300, 21119661, 31088831","abstracts":"Siefker-Radtke et al. Abstract#4503, ASCO 2018: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4503\\r"},{"gene":"HRAS","alteration":"Oncogenic Mutations","cancerType":"Head and Neck Squamous Cell Carcinoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"24240680, 12497061","abstracts":"Ho, A. et al. Abstract# PR08, Molecular Cancer Therapeutics, 2019.: https://mct.aacrjournals.org/content/18/12_Supplement/PR08 &Ho et al. Abstract# TPS2618, JCO 2017: https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS2618\\r"},{"gene":"IDH1","alteration":"Oncogenic Mutations","cancerType":"Cholangiocarcinoma ","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":null,"abstracts":"Abou-Alfa et al. Abstract# LBA10_PR, ESMO 2019: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2019-Congress/ClarIDHy-A-global-phase-3-randomized-double-blind-study-of-ivosidenib-IVO-vs-placebo-in-patients-with-advanced-cholangiocarcinoma-CC-with-an-isocitrate-dehydrogenase-1-IDH1-mutation\\r"},{"gene":"JAK2","alteration":"PCM1-JAK2 Fusion","cancerType":"Chronic Eosinophilic Leukemia, NOS","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"22899477, 23630205, 23400675, 25260694, 22875628, 25207766, 25515960, 26202607","abstracts":null},{"gene":"KIT","alteration":"Oncogenic Mutations","cancerType":"Melanoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"23775962, 21642685 NCCN Guidelines: Soft Tissue Sarcoma  Version 4.2019-September 12, 2019","abstracts":null},{"gene":"KIT","alteration":"Oncogenic Mutations","cancerType":"Thymic Tumor","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"14991904, 25592632, 20571495 NCCN Guidelines: Soft Tissue Sarcoma  Version 4.2019-September 12, 2019","abstracts":null},{"gene":"KIT","alteration":"D816","cancerType":"Mastocytosis","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"29233825, 30274985","abstracts":"DeAngelo et al. Blood 2017 130:2, ASH 2017: https://ashpublications.org/blood/article/130/Supplement%201/2/71272/Clinical-Activity-in-a-Phase-1-Study-of-Blu-285-a\\r"},{"gene":"KRAS","alteration":"Oncogenic Mutations","cancerType":"Colorectal Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"21228335, 20619739, 18316791, 20921465, 24024839","abstracts":null},{"gene":"KRAS","alteration":"G12C","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":null,"abstracts":"Govindan et al. Abstract# ESMO 2019: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2019-Congress/Phase-1-Study-of-AMG-510-a-Novel-Molecule-Targeting-KRAS-G12C-Mutant-Solid-Tumors\\r"},{"gene":"KRAS","alteration":"Oncogenic Mutations","cancerType":"Histiocytosis","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"30867592, 29236635","abstracts":null},{"gene":"MAP2K1","alteration":"Oncogenic Mutations","cancerType":"Histiocytosis","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"25370473, 25351745, 26324360, 26566875, 30867592","abstracts":"Papapanagiotou et al. JCOPO, 2017: https://ascopubs.org/doi/10.1200/PO.16.00070\\r"},{"gene":"MAP2K1","alteration":"Oncogenic Mutations","cancerType":"Low-Grade Serous Ovarian Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"25370473, 25351745, 26324360, 26566875, 30867592","abstracts":"Papapanagiotou et al. JCOPO, 2017: https://ascopubs.org/doi/10.1200/PO.16.00070\\r"},{"gene":"MAP2K1","alteration":"Oncogenic Mutations","cancerType":"Melanoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"25370473, 25351745, 26324360, 26566875, 30867592","abstracts":"Papapanagiotou et al. JCOPO, 2017: https://ascopubs.org/doi/10.1200/PO.16.00070\\r"},{"gene":"MAP2K1","alteration":"Oncogenic Mutations","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"25370473, 25351745, 26324360, 26566875, 30867592","abstracts":"Papapanagiotou et al. JCOPO, 2017: https://ascopubs.org/doi/10.1200/PO.16.00070\\r"},{"gene":"MAP2K2","alteration":"Oncogenic Mutations","cancerType":"Histiocytosis","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"30867592, 29236635","abstracts":null},{"gene":"MDM2","alteration":"Amplification","cancerType":"Liposarcoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"23400593, 23084521","abstracts":"Bauer T et al. Abstract# 11514, JCO 2018: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.11514\\r"},{"gene":"MET","alteration":"Amplification","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"21623265, 26729443 NCCN Guidelines: Non-Small Cell Lung Cancer, Version 7.2019- August 30 2019","abstracts":null},{"gene":"MET","alteration":"Amplification","cancerType":"Renal Cell Carcinoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"27462141, 27279544 NCCN Guidelines: Kidney Cancer Version 2.2020, August 5, 2019","abstracts":null},{"gene":"MET","alteration":"Exon 14 splice mutations","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"21623265, 25971939, 26729443,  NCCN Guidelines: Non-Small Cell Lung Cancer, Version 7.2019- August 30 2019 27693535 21918175","abstracts":"Schuler et al. Abstract# 9067, ASCO 2016: https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9067\\r"},{"gene":"MTOR","alteration":"E2014K, E2419K","cancerType":"Bladder Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"24625776, 23551593","abstracts":null},{"gene":"MTOR","alteration":"L1460P, L2209V, L2427Q","cancerType":"Renal Cell Carcinoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":26831717,"abstracts":null},{"gene":"MTOR","alteration":"Q2223K","cancerType":"Renal Cell Carcinoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":24622468,"abstracts":null},{"gene":"NRAS","alteration":"Oncogenic Mutations","cancerType":"Colorectal Cancer","specimen":"FFPE","fdaLevel":"Level 2","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"20619739, 25110411, 24024844, 24024839","abstracts":null},{"gene":"NRAS","alteration":"Oncogenic Mutations","cancerType":"Histiocytosis","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"30867592, 29236635","abstracts":null},{"gene":"NRAS","alteration":"Oncogenic Mutations","cancerType":"Melanoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"28284557, 16273091 22983396, 30819666","abstracts":"Schuler et al. Abstract #9519, ASCO 2017: https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9519\\r"},{"gene":"NRAS","alteration":"Oncogenic Mutations","cancerType":"Thyroid Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"23406027, 22105174","abstracts":null},{"gene":"NRAS","alteration":"Oncogenic Mutations","cancerType":"Colorectal Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"20619739, 25110411, 24024844, 24024839","abstracts":null},{"gene":"PDGFRA","alteration":"Oncogenic Mutations","cancerType":"Gastrointestinal Stromal Tumor","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"22718859 NCCN Guidelines: Soft Tissue Sarcoma, Version 4.2019-September 12, 2019","abstracts":null},{"gene":"PDGFRA","alteration":"D842V","cancerType":"Gastrointestinal Stromal Tumor","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"29710216, 24963404, 15928335, 12949711, 22718859, 18794084, 22745105, 15685537, 18955458, 25905001, 23752188, 17087936 NCCN Guidelines: Soft Tissue Sarcoma, Version 4.2019-September 12, 2019","abstracts":"Trent et al. Abstract# 10006, ASCO 2011: https://ascopubs.org/doi/10.1200/jco.2011.29.15_suppl.10006\\r"},{"gene":"PTCH1","alteration":"Truncating Mutations","cancerType":"Embryonal Tumor","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"24523439, 24900187","abstracts":null},{"gene":"PTCH1","alteration":"Truncating Mutations","cancerType":"Skin Cancer, Non-Melanoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"24523439, 24900187 22670903, 22670904, 29320312","abstracts":null},{"gene":"RAF1","alteration":"Oncogenic Mutations","cancerType":"Histiocytosis","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"30867592, 29236635","abstracts":null},{"gene":"RET","alteration":"Fusions","cancerType":"Non-Small Cell Lung Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"23533264, 27825636, 28447912,  NCCN  Guidelines Non-Small Cell Lung Cancer, Version 7.2019- August 30 2019 27803005 29657135 29912274, 31485557","abstracts":"Drilon et al. Abstract# 102, ASCO 2018: https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.102\\r"},{"gene":"RET ","alteration":"Oncogenic Mutations","cancerType":"Medullary Thyroid Cancer","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"29657135 29912274","abstracts":"Drilon et al. Abstract# 102, ASCO 2018: https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.102\\r"},{"gene":"TSC1","alteration":"Oncogenic Mutations","cancerType":"Renal Cell Carcinoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"26831717, 30327302 NCCN Guidelines, Kidney Cancer, Version 2.2020, August 5, 2019","abstracts":null},{"gene":"TSC2","alteration":"Oncogenic Mutations","cancerType":"Renal Cell Carcinoma","specimen":"NA","fdaLevel":"Level 3","fdaApproval":null,"drugLabel":null,"drugLabelDate":null,"pmids":"26831717, 30327302 NCCN Guidelines, Kidney Cancer, Version 2.2020, August 5, 2019","abstracts":null}]';

function initialDrug(drugs: any, newDrug: string) {
  if (!drugs[newDrug]) {
    drugs[newDrug] = {};
  }
}

function splitTreatment(str: string, regex: RegExp, stringSplit: string) {
  const treatments: any[] = [];
  (str.match(regex) || []).forEach(matchedItem => {
    const result = matchedItem.split(stringSplit);
    if (result.length > 0) {
      treatments.push({
        drugs: result[0].split('+').map(item => item.trim()),
        fdaApproval: result[1] === 'http:' ? '' : result[1]
      });
    }
  });
  return treatments;
}

function splitAssign(
  drugs: any,
  str: string,
  propertyToAdd: string,
  regex: RegExp,
  stringSplit: string
) {
  (str.match(regex) || []).forEach(matchedItem => {
    const result = matchedItem.split(stringSplit);
    if (result.length !== 2) {
      console.error(matchedItem);
    } else {
      const drug = result[0].trim();
      initialDrug(drugs, drug);
      drugs[drug][propertyToAdd] = result[1].trim();
    }
  });
}

function splitAbstracts(data: any, str: string) {
  const ABSTRACT_REGEX = /[^&]*:\s*http[^&]+/g;
  const abstracts: any[] = [];
  ((str || '').match(ABSTRACT_REGEX) || []).forEach(matchedItem => {
    const result = matchedItem.split(/:\s*http/);
    if (result.length !== 2) {
      console.error(matchedItem);
    } else {
      abstracts.push({
        abstract: result[0].trim(),
        link: `http${result[1].trim()}`
      });
    }
  });
  data.abstractList = abstracts;
}

function getContent() {
  return _.map(JSON.parse(FDA_ORIGIN_DATA), (row: any) => {
    const DRUG_REGEX = /[\w+\s-]+:\s*http[^\s]+/g;
    const DRUG_DATE_REGEX = /[\w+\s-]+:\s*\([\d/]+\)/g;
    // get fda approval
    row.treatments = splitTreatment(row.fdaApproval || '', DRUG_REGEX, ': ');

    const drugs = {};
    // get drug label
    splitAssign(drugs, row.drugLabel || '', 'drugLabel', DRUG_REGEX, ': ');

    // get drug date
    splitAssign(
      drugs,
      row.drugLabelDate || '',
      'drugLabelDate',
      DRUG_DATE_REGEX,
      ':'
    );
    row.drugs = drugs;

    splitAbstracts(row, row.abstracts);

    /// get pmids and nccn
    if (!row.pmids) {
      row.pmids = '';
    }

    const pmids = row.pmids.toString().split('NCCN');
    if (pmids.length > 1) {
      row.nccn = `NCCN ` + pmids[1].trim();
    }
    if (pmids.length > 0) {
      row.pmids = pmids[0].trim();
    }

    const SEPARATOR = ', ';
    row.referenceStr = [
      row.abstractList.length > 0 ? 'abstract' : '',
      row.abstractList
        .map((abstract: any) => abstract.abstract)
        .join(SEPARATOR),
      _.keys(row.drugs).join(SEPARATOR),
      row.pmids.length > 0 ? 'pmid' : '',
      row.pmids,
      row.nccn
    ].join(SEPARATOR);

    delete row.fdaApproval;
    delete row.drugLabel;
    delete row.drugLabelDate;

    return row;
  });
}

const DrugLabel: React.FunctionComponent<{ drug: any }> = props => {
  const drugLabelText = `drug label ${
    props.drug.drugLabelDate ? props.drug.drugLabelDate : ''
  }`;
  return props.drug.drugLabel ? (
    <Linkout link={props.drug.drugLabel}>{drugLabelText}</Linkout>
  ) : (
    <span className={styles.linkOutText}>{drugLabelText}</span>
  );
};

function hasDrugLabelInfo(treatment: any, drugs: any) {
  return _.some(treatment.drugs, drug => _.has(drugs, drug));
}

function getTreatmentDrugLabels(treatment: any, drugs: any) {
  if (treatment.drugs.length > 1) {
    return (
      <DefaultTooltip
        overlay={
          <>
            {treatment.drugs.map((drug: any) => (
              <div>
                {drug}: <DrugLabel drug={drugs[drug]} />
              </div>
            ))}
          </>
        }
      >
        <span className={styles.linkOutText}>drug label</span>
      </DefaultTooltip>
    );
  } else {
    return <DrugLabel drug={drugs[treatment.drugs[0]]} />;
  }
}
export function getReferenceCell(data: any) {
  let treatments: JSX.Element[] = [];
  _.each(data.treatments, (treatment: any) => {
    const treatmentName = treatment.drugs.join('+');
    const fdaText = 'FDA-approval announcement';
    const fdaElement = treatment.fdaApproval ? (
      <Linkout link={treatment.fdaApproval}>{fdaText}</Linkout>
    ) : (
      <span>{fdaText}</span>
    );

    if (treatment.fdaApproval) {
      treatments.push(
        <div key={treatmentName}>
          {treatmentName}: {fdaElement}{' '}
          {hasDrugLabelInfo(treatment, data.drugs) ? (
            <span>and {getTreatmentDrugLabels(treatment, data.drugs)}</span>
          ) : (
            ''
          )}
        </div>
      );
    } else {
      treatments.push(
        <div key={treatmentName}>
          {treatmentName}:
          {hasDrugLabelInfo(treatment, data.drugs) ? (
            <span> {getTreatmentDrugLabels(treatment, data.drugs)}</span>
          ) : (
            ''
          )}
        </div>
      );
    }
  });

  const uniqueDrugsInTreatment = _.uniq(
    _.reduce(
      data.treatments,
      (acc, next) => {
        acc = acc.concat(next.drugs);
        return acc;
      },
      []
    )
  );
  const drugsNotInTreatmentList = _.filter(
    _.keys(data.drugs),
    drug => !_.includes(uniqueDrugsInTreatment, drug)
  );
  treatments = treatments.concat(
    drugsNotInTreatmentList.map(drug => (
      <div>
        {drug}: <DrugLabel drug={data.drugs[drug]} />
      </div>
    ))
  );
  const renderContent = [];

  if (treatments.length > 0) renderContent.push(<div>{treatments}</div>);

  if (data.pmids)
    renderContent.push(
      <div>
        <PMIDLink pmids={data.pmids} />
      </div>
    );

  if (data.abstractList.length > 0)
    renderContent.push(
      <div>
        Abstract(s):{' '}
        {concatElementsByComma(
          data.abstractList.map((abstract: any) => (
            <Linkout link={abstract.link}>{abstract.abstract}</Linkout>
          ))
        )}
      </div>
    );

  if (data.nccn) renderContent.push(<div>{data.nccn}</div>);
  return (
    <div key={data.alteration}>{concatElements(renderContent, <br />)}</div>
  );
}

export type FdaVariant = {
  cancerType: string;
  level: string;
  specimenType?: string;
  alteration: string;
  references: any;
  referenceStr: string;
};

export function getFdaData(hugoSymbol: string): FdaVariant[] {
  const fdaData = _.groupBy(getContent(), 'gene');
  return (fdaData[hugoSymbol] || []).map(record => {
    return {
      cancerType: record.cancerType,
      level: record.fdaLevel,
      specimenType: record.specimen ? record.specimen : 'NA',
      alteration: record.alteration,
      references: record,
      referenceStr: record.referenceStr
    };
  });
}
